Acta Scientific Pharmacology

Short Communication Volume 4 Issue 5

Nicotinamide, Folic Acid and Derivatives as Potent Inhibitors of Inflammatory Factors against Novel Corona Virus Infection

Hemanth Kumar Manikyam1* and Sunil K Joshi2

1Faculty of Science, North East Frontier Technical University, Arunachal Pradesh, India 2Assistant Professor, Cellular Immunology/Hemoglobinopathies, Division of Hematology/Oncology and Bone Marrow Transplantation, Department of Paediatrics, University of Miami Miller School of Medicine, Miami, FL, USA

*Corresponding Author: Hemanth Kumar Manikyam, Faculty of Science, North East Frontier Technical University, Arunachal Pradesh, India.

Received: March 20, 2020; Published: April 16, 2020

×

A novel coronavirus designated as SARS-CoV-2 in February 2020 by World Health organization (WHO) was identified as main cause of SARS like pneumonia cases in Wuhan city in Hubei Province of China at the end of 2019. This been recently declared as Global Pandemic by WHO. There is a global emergency to identify potential drugs to treat the SARS-CoV-2. Currently, there is no specific treatment against the new virus. There is an emergency to identifying potential antiviral agents to combat the disease is urgently needed. An effective and quick approach is to test existing antiviral drugs against. Patients affected with Novel coronavirus had shown severe respiratory inflammatory burst which includes sever cytokine and lymphocyte over responses.

×

Citation

Citation: Hemanth Kumar Manikyam and Sunil K Joshi. “Nicotinamide, Folic Acid and Derivatives as Potent Inhibitors of Inflammatory Factors against Novel Corona Virus Infection". Acta Scientific Pharmaceutical Sciences 4.5 (2020): 27.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


Contact US